

REC Ref.	IRAS No.	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
18/NW/0107	236834	PHIL evaluation in the endovascular treatment of intracranial cerebral ArterioVenous Malformation	Number Agreed	6	6	Date Agreed	31/08/2019	0	26/10/2018	0	Withdrawn By Sponsor
18/LO/0666	242700	Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).	Number Agreed	2	2	Date Agreed	01/07/2020	2	22/10/2018	2	Recruitment Finished
18/LO/1063	236384	The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo-controlled, Phase 3b study-Actellion - AC-065A308	Range Agreed	1	3	Date Agreed	29/12/2018	2	29/12/2018	2	Recruitment Finished
17/NE/0151	223815	Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia (SGI-110-06).	Number Agreed	2	2	Date Agreed	31/12/2018	0	14/09/2018	0	Withdrawn By Sponsor
17/SC/0394	229032	An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinini	Number Agreed	3	3	Date Agreed	31/12/2018	4	12/12/2018	4	Recruitment Finished
17/EE/0026	220207	A Prospective, Randomized, Controlled, Multi-Center Clinical Study of theACRYSOF IQ Extended Depth of Focus (EDF) IOL	Number Agreed	10	10	Date Agreed	30/07/2018	11	30/07/2018	11	Recruitment Finished
17/EM/0236	221138	Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (EDS) in Parkinson's Disease(PD).	Number Agreed	4	4	Date Agreed	31/07/2018	3	31/07/2018	3	Recruitment Finished
17/EE/0177	220722	A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SvD) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM).	Number Agreed	3	3	Date Agreed	01/06/2020	7	26/09/2018	7	Recruitment Finished
17/EM/0154	222912	A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy,Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications ofLevodopa Therapy in Sub	Number Agreed	4	4	Date Agreed	01/12/2018	5	01/12/2018	5	Recruitment Finished
17/LO/0863	228208	EU- Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy use in secondary and primary care - Da Vinci	Number Agreed	45	45	Date Agreed	30/04/2018	43	20/11/2018	43	Recruitment Finished
17/SC/0122	224090	AR101 Trial in Europe Measuring Oral Immunotherapy Success in Peanut Allergic Children	Number Agreed	12	12	Date Agreed	01/12/2017	12	01/12/2018	15	Recruitment Finished
17/SC/0291	226509	The DEFINE PCI study: Physiologic assessment of coronary stenosis following PCI.	Number Agreed	20	20	Date Agreed	31/03/2019	7	28/01/2019	7	Withdrawn By Sponsor
17/NW/0180	220257	A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in SubjectsWith Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations WhoFailed Previous Therapy.	Number Agreed	2	2	Date Agreed	28/02/2018	1	08/08/2018	1	Recruitment Finished
17/EE/0079	220827	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168(Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantlywith Rituximab or Cyclophosp	Number Agreed	1	1	Date Agreed	31/12/2018	1	31/12/2018	1	Recruitment Finished

16/NE/0067	199159	A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson's Disease.	Number Agreed	4	4	Date Agreed	31/12/2017	6	03/12/2018	6	Recruitment Finished
16/EE/0357	206501	Efficacy and safety of opicapone in clinical practice in Parkinson's Disease patients with wearing-off motor fluctuations	Number Agreed	4	4	Date Agreed	30/11/2017	8	18/10/2018	8	Recruitment Finished
17/LO/0052	212454	Evaluation of Uterine Patency following Sonography-guided Transcervical Ablation of Fibroids	Number Agreed	10	10	Date Agreed	01/11/2018	9	28/09/2018	9	Recruitment Finished
16/LO/1244	200385	A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy	Number Agreed	3	3	Date Agreed	31/03/2019	3	12/11/2018	4	Recruitment Finished
16/WM/0271	200160	Prospective, Single-Arm, Multi-Centre Study to Evaluate the Contour Neurovascular System?	Number Agreed	10	10	Date Agreed	07/07/2021	5	12/09/2018	5	Recruitment Finished
16/LO/0675	147355	A PHASE 2, INTERNATIONAL, MULTICENTER, RANDOMIZED, OPENLABEL, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) ALONE AND IN COM+H768BINATION WITH DURVALUMAB (MEDI4736) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WH	Number Agreed	3	3	Date Agreed	31/10/2019	0	03/07/2018	0	Withdrawn By Sponsor
16/LO/0443	197312	A multicentre, open-label, multiple-dose study to evaluate the safety, tolerability and efficacy of UCB7665 in subjects with primary immune thrombocytopenia (ITP)	Number Agreed	1	1	Date Agreed	30/12/2018	1	30/12/2018	1	Recruitment Finished
16/YH/0083	192397	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab Paclitaxel and Gemcitabine in Subject	Number Agreed	10	10	Date Agreed	30/04/2019	11	26/11/2018	11	Recruitment Finished
15/WM/0453	172946	A Open Label, Randomised, Pre-surgical, Pharmacodynamics Study to Compare the Biological Effects of AZD9496 versus Fulvestrant in Postmenopausal Women with estrogen receptor positive HER-2 negative Primary Breast Cancer	Number Agreed	05/01/1900	05/01/1900	Date Agreed	30/11/2018	2	30/11/2018	2	Recruitment Finished
16/NE/0023	190035	A Phase III, Multi-centre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study with Open-Label Extension of Crenezumab in Patients with Prodromal-to-Mild Alzheimer's Disease	Number Agreed	08/01/1900	08/01/1900	Date Agreed	01/08/2018	8	01/08/2018	8	Recruitment Finished
15/SC/0616	188838	An exploratory, randomised, double-blind, placebo-controlled study of the effects of dupilumab on airway inflammation of adults with persistent asthma	Number Agreed	03/01/1900	03/01/1900	Date Agreed	27/07/2017	1	17/10/2018	1	Recruitment Finished